Parameter
| Biomarker | CYFRA21-1 | Full name | Cytokeratin 19 fragment 21-1 | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Diagnosis |
| Disease | Cervical Cancer | Disease Subtypes | / | ||
| Organ | Cervix | Test Sample / Technology Platform | Serum (ELISA, CLIA, chemiluminescence method) | ||
| Pathobiological Mechanisms | The cytoskeletal fragments released by epithelial-derived tumor cells after apoptosis, are highly expressed in cervical squamous cell carcinoma. | ||||
| Clinical Availability Status | Clinical validation / Auxiliary use: As a supplementary marker for SCC, it is used for evaluating the therapeutic effect of squamous cell carcinoma. | ||||
| Notes and Dynamics | The sensitivity for stage I-II cervical cancer is 55% - 65%, which is superior to that of SCC in the early stage; combined with SCC, the early warning of recurrence can be advanced by 1 - 3 months. | ||||